Hematology in COVID-19 patients

The study of blood-related difficulties in COVID-19 individuals who have the SARS-CoV-2 virus infection is referred to as haematology. It has been discovered that COVID-19 has a variety of effects on the blood system, including irregular blood coagulation, anaemia, and low platelet counts.
In severe COVID-19 patients, abnormal blood clotting is a frequent consequence that can result in life-threatening conditions including stroke and pulmonary embolism. These patients' care may involve haematologists, who may prescribe anticoagulant medications to stop blood clotting.
 
COVID-19 can also cause anemia, a condition in which there is a deficiency of red blood cells, which can lead to fatigue, weakness, and shortness of breath. Hematologists may perform blood transfusions or prescribe medications to treat anemia in COVID-19 patients.
 
Low platelet counts, a condition known as thrombocytopenia, have also been reported in some COVID-19 patients. This can lead to an increased risk of bleeding and may require platelet transfusions or other treatments.
 
 

  • Hematologic Manifestations of COVID-19
  • Coagulopathy in COVID-19 Patients
  • COVID-19 and Hematopoietic Stem Cell Transplantation
  • Impact of COVID-19 on the Diagnosis and Management of Hematologic Malignancies

Related Conference of Hematology in COVID-19 patients

February 24-25, 2025

4th European Congress on Hematology

Madrid, Spain
May 05-06, 2025

21st Global Summit on Hematology and Blood Disorders

Rome, Italy
July 07-08, 2025

23rd World Hematology Congress

Zurich, Switzerland

Hematology in COVID-19 patients Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in